Navigation Links
Amarin Signs Agreement to Acquire Ester Neurosciences
Date:12/5/2007

Adds Promising Phase II Neurology Candidate

$8.1 Million Financing in Connection With Acquisition

Reverse Stock Split Planned for January 2008

LONDON, December 5 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Company has:

- Signed an agreement to acquire Ester Neurosciences Limited ("Ester"), a private research and development company based in Israel. The acquisition is expected to close tomorrow. The initial consideration is $15 million, plus up to $17 million in contingent payments. Ester's core assets include (i) a platform messenger RNA (mRNA) silencing technology which targets the cholinergic pathway; (ii) EN101, a Phase II compound with promising efficacy data for the treatment of myasthenia gravis ("MG") utilising this technology; and (iii) a preclinical program in neurodegenerative and inflammatory diseases.

- Received financing commitments for approximately $8.1 million in gross proceeds in connection with public offerings of equity, three-year convertible debt and warrants. Directors and officers committed $1.7 million. The financing is expected to close this week.

- Resolved to hold a General Meeting in January 2008 at which the Company's shareholders will be asked to approve a 1-for-10 reverse stock split, which is part of Amarin's definitive plan to regain and sustain compliance with Nasdaq listing requirements.

Rick Stewart, Chief Executive Officer of Amarin, commented, "We are delighted to announce the signing of the Ester acquisition, which is an excellent strategic fit for Amarin. This acquisition allows Amarin to gain access to a unique mRNA platform technology based on breakthrough
'/>"/>

SOURCE Amarin Corporation Plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
2. Amarin to Present at 4th Annual Bio Investor Forum
3. Amarin Announces Initiation of Cardiovascular Development Strategy
4. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
5. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
6. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
7. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
8. Monsanto Company Signs Share Subscription Agreement With Devgen
9. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
10. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
11. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... made great strides in saving China,s endangered national treasure, ... 65 giant panda reserves that have been established and ... 1596 pandas remain in the wild. , Breeding ... the panda by improving genetic diversity, avoid inbreeding and ... are these high-profile programs doing so far? , In ...
(Date:7/23/2014)... Shimadzu Scientific Instruments has launched the ... developed jointly with Ajinomoto Co. Inc. Offering simultaneous ... amino acids in nine minutes, drastically enhancing laboratory ... utilizing a fast application-specific column and an LCMS-2020 ... even under conditions with difficult samples that contain ...
(Date:7/23/2014)... AVIV, Israel , July 23, 2014 /PRNewswire/ ... ., a portfolio company of Trendlines Agtech ... one of Israel,s leading ... http://photos.prnewswire.com/prnh/20140121/666259-a) , Valentis,s technology combines nanocrystalline ... plant pulp waste, with additional nanoparticles to produce ...
(Date:7/23/2014)... 2014  GrowBLOX Sciences, Inc. (OTCQB: GBLX), a medical cannabis ... for two medical marijuana dispensary locations in Las ... the Clark County, Nevada dispensary for ... previously announced.  GrowBLOX Sciences, CEO Craig Ellins ... applications for dispensaries in the City of Las ...
Breaking Biology Technology:Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3
... 3 ,HemoGenix(R) and ORF Genetics announce the collaboration ... for use in all HALO(R),Assay Kits and HALO(R) ... cells is detected. , ... of growth factors and cytokines using,barley seed as ...
... , QUEBEC CITY, Dec. ... AEZS ; TSX: AEZ), a global biopharmaceutical company focused ... completed the transaction under the previously announced purchase and ... relating to AEterna Zentaris, rights to royalties on future ...
... announces the exclusive licensing of DxS Scorpions™ technology to test for ... and targeted control of contaminant microbes can increase profitability. , ... ... ETS has had the exclusive license to use this technology in ...
Cached Biology Technology:HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Research Services 2HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Research Services 3AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 2AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 3ETS Laboratories Offers New Process Optimization Tools to the Fuel Ethanol Industry 2
(Date:7/23/2014)... using tissue samples cultured from cystic fibrosis patients, scientists ... Marsico Lung Institute have shown that a new CF ... CF drug. , The finding, published today in the ... mutant CFTR protein becomes unstable and loses its ability ... two drugs. The research offers several insights into how ...
(Date:7/23/2014)... , , , , ... , , , , ... extend healthy lifespan. The idea, they argue, would be to target the... , , ... , , , , , ... , , , , , , , Medicine focuses almost ...
(Date:7/23/2014)... Roughly 780 million people around the world have no ... Health Organization (WHO), 3.4 million people die from water-related ... the goal of making a contribution to solving this ... Wendelin Stark, head of the Functional Materials Laboratory, the ... developing a prototype. , "What makes our DrinkPure filter ...
Breaking Biology News(10 mins):UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5ETH student develops filter for clean water around the world 2
... Boston, MA (Jan. 18, 2012) The National ... Research Institute, a subsidiary of Mass. Eye and Ear, ... understand the origins of eye allergies (NEI Grant Number ... principal investigator for the project formally entitled "Cellular and ...
... new approach to motion capture technology is offering fresh ... general. Researchers studied three types of tennis serves, ... which creates the highest potential for shoulder injury. ... Annals of Biomedical Engineering , could aid sports training ...
... of microbiologists led by Indiana University researchers has identified a ... single end or pole of the cell instead of uniform, ... that could have implications in the development of new antibacterial ... bacteria such as Escherichia coli and Bacillus ...
Cached Biology News:Markerless motion capture offers a new angle on tennis injuries 2Markerless motion capture offers a new angle on tennis injuries 3Markerless motion capture offers a new angle on tennis injuries 4Polar growth at the bacterial scale reveals potential new targets for antibiotic therapy 2Polar growth at the bacterial scale reveals potential new targets for antibiotic therapy 3
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... Serotec STAR3000 HISTAR detection systems ... to be used with species specific ... in tissue specimens. Visualisation is accomplished ... that utilises novel polymer labelling technology. ...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
... AmpliTaq DNA Polymerase is ... the PCR process, a testimony to its ... activity profile makes it ideal for PCR ... to guarantee reproducible results. ,, AmpliTaq ...
Biology Products: